A highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. Binds within the ATP pocket of the active kinase (Kd
= 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α
= 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38β
2 respectively). Promotes stability of naive human pluripotent stem cells in culture. Also available as part of the MAPK Inhibitor Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of GlaxoSmithKline
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Davies et al.
The activation of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
Frantz et al.
Characterization of the structure and function of a new mitogen-activated protein kinase (p38β).
Jiang et al.
Induction of apoptosis by SB 202190 through inhibition of p38β mitogen-activated protein kinase.
Nemoto et al.
Derivation of novel human ground state naive pluripotent stem cells.
Gafni et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 202190 include:
Showing Results 1 - 10 of 18